Each month, MLO’s Editor in Chief, Christina Wichmann, interviews a lab leader. Thomas P. Slavin Jr., MD, MBA, FACMGG, DABMD is Medical Laboratory Observer’s April Lab Innovator!
Thomas P. Slavin Jr., MD, MBA, FACMGG, DABMD is the Chief Clinical Officer, Molecular Oncology and Medical Director, Haystack Oncology at Quest Diagnostics. Dr. Slavin is a physician-scientist and biotech executive, triple-board-certified in clinical genetics, molecular diagnostics and pediatrics. He previously held the positions of Chief Medical Officer at Myriad Genetics and Chief Scientific Officer at HALO Precision Diagnostics. He was a former assistant professor in the departments of Medical Oncology and Population Sciences at City of Hope National Medical Center. Dr. Slavin graduated medical school with Alpha-Omega-Alpha-honors from the University of South Florida. He is an active member of the American Association of Cancer Research, the American Society of Clinical Oncology (ASCO), the Collaborative Group of the Americas on Inherited Colorectal Cancer, and he is a fellow of the American College of Medical Genetics and Genomics. He has served on National Comprehensive Cancer Network (NCCN) committees for both the genetics of and screening for colorectal cancer.
Focused on expanding genetics education for cancer care providers, Dr. Slavin is an active faculty member of City of Hope’s hereditary genomics training program. He is a well-respected researcher in the field of medical genetics, publishing over 80 journal articles collectively evaluating genomic data from over 500,000 patients, multiple book chapters, and providing numerous presentations at national and international medical meetings. He has been involved in many national cancer research grants and was a 2018 National Institutes of Health (NIH) K08-career development grant awardee.
